×
Cassava Sciences EBIT 2010-2024 | SAVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cassava Sciences ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Cassava Sciences EBIT 2010-2024 | SAVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cassava Sciences ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.8B
Chugai Pharmaceutical (CHGCY)
$66.9B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$20B
Astellas Pharma (ALPMY)
$17.7B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$16B
Neurocrine Biosciences (NBIX)
$15.3B
Shionogi (SGIOY)
$12.5B
Orion OYJ (ORINY)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Stevanato Group S.p.A (STVN)
$6.5B
Corcept Therapeutics (CORT)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.9B
Grifols, S.A (GRFS)
$4.8B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Recursion Pharmaceuticals (RXRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.1B
Hypermarcas (HYPMY)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Indivior (INDV)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Evotec AG (EVO)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.4B